Stock Ratings / Industrials / BHST / options

RML (46) STKE (47) CHWM (58) SGLD (47) ⌘ Pro Terminal →

BioHarvest Sciences Inc. (BHST) Options Positioning, Max Pain & Unusual Sweeps

$1.66 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.66

BioHarvest Sciences Inc. (BHST) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $37.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BHST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BHST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, BioHarvest Sciences Inc. (NASDAQ: BHST) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.66 (0.00% 1D, market cap $37.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, BHST ranks #377 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BHST compare to RML and STKE in the Industrials sector?

▼

Within the Industrials sector (Diversified Equities), BHST carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 59.3%, and ROIC of -35.0%. By comparison, RML (Resolution Minerals Ltd) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $44.1M) and STKE (Sol Strategies Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $50.5M). Among the 5-stock peer group, BHST leads on earnings multiple (N/A) while BHST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BHST?

▼

Per BHST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723464), BioHarvest Sciences Inc. generated $34.5M in revenue (+37.0% YoY), -$11.1M in net income, and -$9.6M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.66 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHST)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY BHST SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (20% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 48 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.62+11.1% Next Q

Q2 (-2Q)

Grade E$1.80-6.7% Next Q

Q3 (-1Q)

Grade E$1.68-1.2% Next Q

Current

Grade D-$1.66-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BHST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BHST currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.70) and Max Pain ($1.74) forces dealer call-delta covering toward $10.24.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BHST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BHST)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BHST.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BHST)

✓Walkthrough of BHST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BHST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.90%▼ DESCENDING CHANNEL

2026-11-02O $1.76H $1.76L $1.66C $1.66VOL 20.4K

RES: $2.01SUP: $1.21SMA50: $1.70SMA200: $3.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BHST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BHST Butterfly Map → + Track BHST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +37.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BHST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BHST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BHST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHST)

Industrials Rank #377 of 485 ⚔️ RML vs BHST Full Matrix →

1. Head-to-Head Industrials Peer Comparison (BHST vs. RML, STKE, CHWM, SGLD)

Industry: Diversified Equities (43 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, BioHarvest Sciences Inc. (BHST) ranks #377 by composite RQD confidence (35/100, grade D-) and #418 by equity capitalization ($37.6M). Within this direct 5-issuer industry benchmark cohort, BHST leads on earnings valuation at N/A trailing P/E, while BHST leads on capital efficiency and profitability with -35.0% ROIC and 59.3% gross margin. CHWM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with BHST at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BHST ACTIVE BioHarvest Sciences Inc.	D-	35/100	—	59.3%	-35.0%	0.00%	$37.6M	Benchmark Subject
RML Resolution Minerals Ltd	D	46/100	—	—	—	-2.54%	$44.1M	/rml-vs-bhst →
STKE Sol Strategies Inc.	D	47/100	—	—	—	-3.91%	$50.5M	/stke-vs-bhst →
CHWM Chilwa Minerals Limited American Depository Shares	D+	58/100	—	—	—	-13.34%	$59.6M	/chwm-vs-bhst →
SGLD Scorpio Gold Corporation	D	47/100	—	—	—	-7.20%	$60.1M	/sgld-vs-bhst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001723464

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioHarvest Sciences Inc. (BHST) reported GAAP revenue of $34.5M (+37.0% vs. FY2024 revenue of $25.2M , and +172.3% cumulative change since FY2023) , GAAP net income of -$11.1M, operating cash flow of -$7.2M, and free cash flow of -$9.6M (-0.7% YoY). On the balance sheet, BHST closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$34.5M	-$11.1M	-$7.2M	-$9.6M	—	—
FY2024 (FY)	2024-12-31	$25.2M	-$12.9M	-$6.7M	-$9.5M	—	—
FY2023 (FY)	2023-12-31	$12.7M	-$12.6M	-$8.5M	-$8.5M	—	—

3. BHST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BHST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BHST compare to RML and STKE in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for BHST?

Where is BHST trading relative to its 50-day, 200-day, and 52-week technical levels?

BHST last traded at $1.66 (0.00% on volume of 2,541 shares), positioning the stock -2.35% below its 50-day simple moving average ($1.70) and -48.61% below its 200-day simple moving average ($3.23). Across its 52-week range of $1.37 to $9.75, BHST sits at the 3.5% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.45 to $1.87).

BHST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BHST's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BHST.

Direct Sub-Reports: BHST RQD Cockpit BHST 12M Forecast BHST Earnings & Move BHST Dividends & DRIP BHST Insiders & 13F BHST Whale Options BHST Profit Sankey BHST News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BHST — BioHarvest Sciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:48:00Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BHST scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 6 of 20, reflecting ROIC of -35% and an FCF yield of 0%; for an investor, this means the business is not currently generating returns on invested capital or free cash flow to support valuation. The whale/13F flow pillar scores 6 of 20 on institutional accumulation and options positioning, indicating weak institutional support in the source data. The insider conviction pillar scores 5 of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest of the five, signaling limited insider-driven confidence. The macro regime fit pillar scores 7 of 20 with a beta of 1.0 and a sector sensitivity read, giving little offsetting defensive character. The forensic balance sheet pillar is the strongest at 11 of 20, supported by an Altman Z-Score of 2.5, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.5. Taken together, the upside case rests on balance sheet resilience and the company's recent revenue growth, while the valuation tradeoff is that the stock trades without positive earnings or cash flow to anchor it. The RQD framework is educational and not personalized advice; a prospective investor should weigh these scores against their own objectives.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$34.5M	$-5.6M	$-11.1M	N/A	$-9.6M	$23.0M	N/A
FY 2024	$25.2M	$-7.0M	$-12.9M	N/A	$-9.5M	$2.4M	N/A
FY 2023	$12.7M	$-10.0M	$-12.6M	N/A	$-8.5M	N/A	N/A

Per the SEC financials, revenue grew from $12.7M in FY 2023 to $34.5M in FY 2025, while net losses remained in the $-11.1M to $-12.9M range across all three periods. Operating margin is -16.2% and net margin is -32.3% per the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 5/9, with Debt/Equity at 0.5. Reported cash rose to $23.0M in FY 2025 from $2.4M in FY 2024.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the most recent item is an announcement that third quarter 2026 financial results will be reported on November 12, 2026. Coverage references a Tate & Lyle and Bioharvest milestone in a next-generation sweetener development program, and a headline on the platform's ability to produce a target sweetener within that program. A proprietary olive cell asset is described as advancing to commercial readiness, opening a CDMO licensing opportunity. One item is flagged RED under RISK WATCH, a Q1 2025 earnings headline describing a loss per share slightly wider than expected, though shares were reported to move higher. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links or proprietary signals.

Open Questions

What are the reported EPS, debt figures, and cash balances for FY 2023, which are listed as N/A or not available?
What drives the gap between revenue growth to $34.5M and persistent net losses, and what is the path toward positive operating income?
What do the Tate & Lyle program milestones mean for revenue timing and the commercial readiness of the olive cell asset?
How will the scheduled third quarter 2026 results on November 12, 2026 compare with the FY 2025 trajectory?

BHST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioHarvest Sciences Inc. (BHST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BHST Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 14h ago

BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 17h ago

BioHarvest Sciences (BHST) Institutional Ownership 2026

MarketBeat report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

BHST Q1 2025 Earnings: Loss Per Share Slightly Wider Than Expected, Shares Still Move Higher - Earnings Yield Analysis

https://www.dars.gov.et/ report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Beyond Oil Ltd. (BOIL.TO) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Cizzle Brands Corporation (CZZL.NE) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BHST Bull vs. Bear Conversation Board — What's Your Call at $1.66?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BHST 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.46 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BHST (D- • RQD 35/100) a Buy at $1.66?

Welcome to the BHST (BioHarvest Sciences Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Diversified Equities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.34 (-19.3%)

Spot @ $1.66

Pump the brakes on BHST — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BHST, but look at what you are paying: current EV/EBITDA multiples with 59.3% gross margins. Unless BioHarvest Sciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.11 (+27.1%)

Spot @ $1.66

BHST cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BHST, the market is fixating on short-term headline noise in Diversified Equities and ignoring the balance sheet and cash flow trajectory. At $1.66 (52-wk range $1.37 - $9.75), any beat on forward guidance forces shorts and underweight funds to chase.